2CUREX AB SEK-10 (F:2QE) — Market Cap & Net Worth
Market Cap & Net Worth: 2CUREX AB SEK-10 (2QE)
2CUREX AB SEK-10 (F:2QE) has a market capitalization of $3.49 Million (€2.99 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #28989 globally and #2525 in its home market, demonstrating a 72.55% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 2CUREX AB SEK-10's stock price €0.18 by its total outstanding shares 25102916 (25.10 Million).
2CUREX AB SEK-10 Market Cap History: 2019 to 2026
2CUREX AB SEK-10's market capitalization history from 2019 to 2026. Data shows change from $37.71 Million to $5.28 Million (-21.44% CAGR).
2CUREX AB SEK-10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 2CUREX AB SEK-10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 2QE by Market Capitalization
Companies near 2CUREX AB SEK-10 in the global market cap rankings as of May 5, 2026.
Key companies related to 2CUREX AB SEK-10 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
2CUREX AB SEK-10 Historical Marketcap From 2019 to 2026
Between 2019 and today, 2CUREX AB SEK-10's market cap moved from $37.71 Million to $ 5.28 Million, with a yearly change of -21.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €5.28 Million | +186.31% |
| 2025 | €1.84 Million | +132.59% |
| 2024 | €792.39K | -84.79% |
| 2023 | €5.21 Million | -74.68% |
| 2022 | €20.57 Million | -53.33% |
| 2021 | €44.08 Million | -9.52% |
| 2020 | €48.72 Million | +29.18% |
| 2019 | €37.71 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of 2CUREX AB SEK-10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.49 Million USD |
| MoneyControl | $3.49 Million USD |
| MarketWatch | $3.49 Million USD |
| marketcap.company | $3.49 Million USD |
| Reuters | $3.49 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About 2CUREX AB SEK-10
2cureX AB (publ) operates as a medical technology company in Europe. The company's principal product is IndiTreat, an IVD test for the treatment of cancer by establishing 3D copies of the patient's tumor and directly testing them against therapies. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.